In the publication of the so far largest clinical trial of bardoxolone methyl, the authors refer to the impairment of NRF2 activity-dependent gene transcription that was reported in animal models of CKD as one rational for the clinical application of the substance in CKD [11]. The gene discussed is NFE2L2; the disease is chronic kidney disease.